MIG

What MIG does

MIG Inc. (MIG株式会社) is a Tokyo-based medical innovation company founded in September 2017 that develops and commercializes a VR-based brain health measurement service called Brain100 Studio. The company's core technology uses 3D virtual reality goggles to measure path integration (self-position recognition), targeting grid cell function in the entorhinal cortex — the region where Alzheimer's disease pathology first emerges (Braak stages I/II), based on the 2014 Nobel Prize-winning work of O'Keefe, Moser, and Moser. The non-invasive test detects pre-symptomatic cognitive decline risk in 8-15 minutes, with reported sensitivity of 0.88 and specificity of 0.70, and correlates with blood biomarkers (p-tau, NF-L, GFAP). Two peer-reviewed publications (Brain Communications and Journal of Alzheimer's Disease, both 2024) validate the underlying method.

MIG serves four primary customer segments: healthy working-age individuals (40s-60s) seeking proactive brain health monitoring; corporate wellness programs under Japan's Kenko Keiei (health management) and SDGs initiatives; medical institutions for patient screening and referral pathways; and local governments for community dementia prevention programs. Revenue is generated through subscription-based corporate wellness packages, pay-as-you-go consumer sessions at partner locations, and channel partnership distribution with logistics (Hino Computer System), retail (Aeon MySCUE), energy (Idemitsu Kosan service stations), pharmaceutical (Daiichi Kogyo Seiyaku), and fitness (JEXER) partners. The company operates from headquarters in Shibuya, Tokyo, with a Kansai sales office opened in April 2024, and is led by CEO Hidemi Kai and CSO Akihiko Takashima (35-year Alzheimer's research veteran and former FDA researcher).

The business model combines direct sales for enterprise health-management clients with multi-channel consumer access through retail storefronts, service stations, fitness clubs, and railway stations, supplemented by content marketing via books and national TV media. Funding to date consists primarily of a $932,774 non-equity investment from AXA Life Japan (September 2020), two METI government subsidies, and joint research funding from Kirin Holdings, with capital stock of ¥176,419,800 as of December 2024.

Name

MIG

Legal name

MIG株式会社

Website

https://medicalig.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

MIG Inc. is a Tokyo-based medical innovation company that operates Brain100 Studio, a VR-based brain health measurement service detecting pre-symptomatic Alzheimer's pathology via entorhinal cortex path integration. It serves healthy adults, corporate wellness programs, medical institutions, and local governments in Japan through multi-channel distribution.

Ownership category

akta.pro rank

Product category

Neurological Diagnostics & Dementia Screening Services

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Measuring & Controlling Devices, Nec (3829)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industries

Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ), Memory Care Care Management & Navigation (Dementia Care Coordination) (HLADACAJ)

Keywords

• VR brain health screening
• Alzheimer's early detection
• Cognitive function measurement
• Dementia prevention programs
• Entorhinal cortex assessment

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Brain100 Studio Program — Brain Health VR Measurement Service: MIG provides VR goggle-based brain health measurement services to individuals and corporate employees through partner locations including medical institutions, health-management corporations, and retail/service station locations. Revenue is generated through service fees per measurement session.
2. SDGs / Health Management Corporate Program — Brain Health Package for Employees: MIG sells 'SDGs approach' corporate brain health packages to companies promoting health management and SDGs. Includes VR screening for employees, staff training, online health check follow-ups, and lifestyle improvement advice reports delivered via email. Companies support employees through employee benefit programs.
3. Brain100 Studio — Driver Health Management for Logistics Industry: Partnership with Hino Computer System to provide brain health measurement services to drivers and employees in logistics and transportation companies as part of workplace health management programs.
4. Brain100 Studio + Prevention Solutions (with Daiichi Kogyo Seiyaku): Partnership with Daiichi Kogyo Seiyaku for provision of brain health VR measurement combined with Natriide cognitive supplement for prevention of cognitive decline, sold through Kyoto Station headquarters and corporate wellness programs.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels7 records

Core offering

MIG operates the Brain100 studio service, which uses 3D VR goggles to measure spatial navigation function in the entorhinal cortex for ultra-early detection of Alzheimer's disease pathology (Braak stages I/II) before cognitive symptoms appear. The non-invasive 8-15 minute measurement is offered through medical institutions, corporate wellness programs, local government public health initiatives, and consumer-facing locations such as retail stores, service stations, and fitness clubs.

Product overview

MIGはVRゴーグルを用いた脳健康測定サービス「Brain100 studio」をコア製品として展開。嗅内野のGrid細胞機能を測定し、アルツハイマー病の超早期(ステージI/II)段階の認知機能低下リスクを検出する「脳健康VR測定」技術を基盤としている。医療機関様向けモデル、健康経営企業向けモデル、地方自治体様モデルなど複数の提携形態で社会実装を進めており、Brain100 studioプログラムとして検査から予防活動サポートまで一貫して提供

Differentiator

Problem solved

Functional benefit

Brands

• Brain100 studio: VR brain health measurement service that detects ultra-early-stage cognitive decline associated with Alzheimer's disease, targeting the entorhinal cortex spatial navigation function.

Products and services

• Brain100 studio (Brain Health VR Measurement Service) VR goggle-based 8-15 minute non-invasive brain health measurement service that quantifies spatial navigation function in the entorhinal cortex, detecting pre-symptomatic Alzheimer's disease pathology (Braak stages I/II) before cognitive decline manifests. Available to consumers through retail, fitness, and service station locations.
• SDGs Approach Corporate Brain Health Package Corporate brain health program package for health-management and SDGs-promoting enterprises, including VR screening for employees, staff training, online health check follow-ups, and individual lifestyle improvement advice reports.
• Brain100 Studio Driver Health Management Program Brain health measurement service tailored for logistics and transportation industry drivers and employees as part of workplace health management programs to address the logistics 2024 problem.
• Medical Institution Partnership Model (院内/出張実施) VR brain health measurement service delivered within medical institutions (hospitals/clinics) or through visiting service format, providing referral pathways to follow-up medical care for patients identified with early-stage risk.
• Local Government Public Health Program

Quantifiable outcome

• 49% of people in their late 40s already have early-stage Alzheimer's pathology in the entorhinal cortex (Braak stage I/II)
• +4 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

14 partnerships are on record, tiered core and minor.

• 第一工業製薬株式会社 (Daiichi Kogyo Seiyaku Co., Ltd.)coreChannel Partner/ Reseller/ Distributor · 1 September 2024Daiichi Kogyo Seiyaku signed a partner contract in September 2024 to distribute MIG's Brain100 studio and combined it with their 'Natriide' (caterpillar fungus component) cognitive supplement. Services offered at Kyoto Station new headquarters, internal corporate adoption, and external service provision. Aims for cognitive health life extension.
• イオンリテール株式会社 (Aeon Retail Co., Ltd.)coreChannel Partner/ Reseller/ Distributor · 1 September 2024Aeon Retail provides retail storefront for MIG's brain health VR measurement through their senior care brand 'MySCUE' (マイスキュー). MySCUE at Aeon Style Shinagawa Seaside opened September 12, 2024. Services include limited-time free campaign trials. MySCUE positions itself as a touchpoint for caregiver information, products, and services.
• 日野コンピューターシステム株式会社 (Hino Computer System Co., Ltd.)coreChannel Partner/ Reseller/ Distributor · 1 July 2024Hino Computer System signed a partner contract with MIG in July 2024 to provide and distribute the Brain100 studio program. The partnership targets the logistics industry to protect driver brain health and reduce accident risks from dementia, contributing to solving Japan's logistics 2024 problem.
• JR東日本商事株式会社 / JR東日本スポーツ株式会社 (JR East Shoji / JR East Sports)minorChannel Partner/ Reseller/ Distributor · 1 May 2023JR East Shoji collaborated with MIG to offer 'Brain Health VR Measurement Events' at JEXER fitness clubs (Ueno, Omiya, Kawasaki) and Relaxze station locations. Events were available to both members and non-members on a reservation basis at campaign pricing.
• 出光興産株式会社 (Idemitsu Kosan Co., Ltd.)minorChannel Partner/ Reseller/ Distributor · 1 March 2023As part of Idemitsu's 'Smart Yorozuya' initiative to transform service stations into lifestyle support hubs, MIG provided brain function measurement services at three service stations in Aichi Prefecture starting March 2023. MIG was commissioned by Idemitsu to conduct the measurements.
• 医療AIプラットフォーム技術研究組合 (HAIP)minorStrategic or Co-development Partner · 1 February 2023MIG participated in HAIP's (Healthcare AI Platform) Phase 3 pilot operations (February 2023). MIG's VR brain health measurement service was listed on HAIP's medical AI/DX service catalog site, expanding visibility among healthcare professionals.
• 株式会社地球の歩き方 (Diamond Inc. / Arukei Arukikata)minorGTM or Marketing Partner · 1 November 2022MIG collaborated with the travel guidebook publisher 'Arukei Arukikata' to publish 'Brain Becoming Stronger! Amazing Arukei Arukikata for Your Brain' (November 2022), co-authored by CSO Takashima. The book explains why travel activates the entorhinal cortex and provides 50 brain training exercises for dementia prevention.
• 東日本旅客鉄道株式会社 (JR East)minorChannel Partner/ Reseller/ Distributor · 1 October 2022JR East invited MIG to participate in its 'Sukoyaka Life Support Station' demonstration experiment at Kumagaya Station (October 2022). MIG offered free VR brain health screening trial demonstrations as part of the station's health support services, validating the concept of railway station-based health screening.
• 株式会社集英社 / 株式会社集英社クリエイティブ (Shueisha / Shueisha Creative)coreGTM or Marketing Partner · 1 February 2022Shueisha and MIG co-published 'JIN-仁-と学ぶ 認知疰「超」早期発見と予防法' (February 2022), using manga characters to explain dementia prevention. Shueisha Creative CEO Suzuki Haruhiko (former Shueisha Managing Director) serves as MIG Executive Advisor since March 2022.
• 藤田医科大学 (Fujita Health University) / 学校法人藤田学園coreStrategic or Co-development Partner · 1 July 2021Fujita Health University signed a joint clinical research contract with MIG in September 2021. The partnership involves AMED-funded research (2021-2024) led by Prof. Watanabe Hiroshisa, examining VR measurement correlation with blood biomarkers (p-tau, NF-L, GFAP).
• 南東北グループ 総合東京病院 (Southern Tohoku Hospital Group / Sogo Tokyo Hospital)coreStrategic or Co-development Partner · 1 July 2021Sogo Tokyo Hospital (南東北グループ) and MIG entered a joint clinical research agreement in July 2021 (research started late July 2021). Study: 'VR goggle-based navigation function and spatial learning ability measurement for quantification of cognitive function.' Research results published in Journal of Alzheimer's Disease (2024).
• 学習院大学 (Gakushuin University)coreStrategic or Co-development Partner · 1 August 2020Gakushuin University signed a commissioned research agreement with MIG in August 2020. CSO Akihiko Takashima serves as Professor at Gakushuin University's Department of Life Sciences. The university collaborated on the AMED project and multiple research publications.
• 経済産業省 (Ministry of Economy, Trade and Industry)minorOthers · 1 April 2020MIG received METI subsidy funding under the 'Commercial Service Competitiveness Enhancement Initiative' in both FY2019 (April 2020) and FY2020 (April 2021). This non-dilutive government funding supported the company's R&D and market validation activities.
• キリンホールディングス株式会社 (Kirin Holdings Co., Ltd.)coreStrategic or Co-development Partner · 1 August 2019KIRIN entered into a joint research agreement with MIG in July 2019. KIRIN provided joint research funding (共同研究費) to MIG. This was one of MIG's earliest corporate partnerships, validating the company's approach to early-stage dementia detection.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Altoida: US-based digital health company that uses augmented reality and machine learning on smartphones/tablets to measure cognitive biomarkers for early Alzheimer's detection. Closely comparable to MIG in its digital neuro-assessment approach targeting pre-symptomatic AD populations.
• Linus Health: Boston-based digital cognitive assessment platform using iPad-based tools (e.g., DCTclock) to detect early signs of cognitive impairment. Targets the same pre-symptomatic AD detection market as MIG via non-invasive digital measurement.
• Cogstate: ASX-listed computerized cognitive testing company serving clinical trials and broader brain health applications. Comparable to MIG in delivering validated digital cognitive assessment, though focused on tablet-based tests rather than VR-based spatial navigation.
• Cambridge Cognition: UK-based provider of computerized cognitive assessments (CANTAB) for research, clinical trials, and healthcare. Comparable as a regulated digital cognitive assessment vendor with FDA-cleared tests targeting the same Alzheimer's research and screening ecosystem as MIG.
• BrainCheck: US digital cognitive assessment platform offering tablet-based tests for concussion, dementia, and mild cognitive impairment screening. Comparable to MIG in delivering fast, non-invasive cognitive screening suitable for clinical and consumer channels.
• Neurotrack Technologies: US digital health company offering cognitive assessment and brain health programs to identify risk of cognitive decline. Comparable to MIG in its consumer-facing, non-invasive digital screening model for early AD risk.

Emerging players

• C2N Diagnostics: US company offering the PrecivityAD blood-based biomarker test for amyloid pathology. Partial overlap with MIG — same end customer (early Alzheimer's risk identification) but different modality (blood biomarker vs. VR cognitive test), making it a complementary or potentially substitutive technology.

Broad incumbents

• Eisai: Japanese pharmaceutical company that developed Lecanemab (Leqembi) for early Alzheimer's disease. Operates broad dementia awareness and diagnostic initiatives. Relevant as a major incumbent shaping the early-AD treatment landscape that MIG's screening tool feeds into.
• Sysmex: Japanese global leader in in-vitro diagnostics with expanding capabilities in blood-based biomarkers and central laboratory testing. Relevant as a large incumbent that could potentially commercialize competing AD biomarker diagnostics at scale in Japan.
• Shimadzu: Japanese manufacturer of analytical and measuring instruments with active neuroscience and biomarker research programs. Comparable as a major Japanese instrumentation incumbent with adjacent capabilities in brain health measurement technologies.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MIG